CRISPR Therapeutics AGCRSP财报
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...
CRSP Q4 2025 Key Financial Metrics
营收
$864.0K
毛利润
N/A
营业利润
$-154.8M
净利润
$-130.6M
毛利率
N/A
营业利润率
-17912.5%
净利率
-15117.2%
同比增长
-97.6%
EPS
$-1.32
资金流向
CRISPR Therapeutics AG Q4 2025 财务摘要
CRISPR Therapeutics AG reported revenue of $864.0K (down 97.6% YoY) for Q4 2025, with a net profit of $-130.6M (down 250.1% YoY) (-15117.2% margin). Cost of goods sold was N/A.
核心财务指标
| 总营收 | $864.0K |
|---|---|
| 净利润 | $-130.6M |
| 毛利率 | N/A |
| 营业利润率 | -17912.5% |
| 报告期 | Q4 2025 |
CRISPR Therapeutics AG 年度营收
CRISPR Therapeutics AG annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.5M). Click any linked year to see what changed vs the prior 10-K.
CRISPR Therapeutics AG 季度营收与净利润历史
CRISPR Therapeutics AG quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $864.0K | -97.6% | $-130.6M | -15117.2% |
| Q3 2025 | $889.0K | +47.7% | $-106.4M | -11973.1% |
| Q2 2025 | $892.0K | +72.5% | $-208.5M | -23379.9% |
| Q1 2025 | $865.0K | +71.6% | $-136.0M | -15722.1% |
| Q4 2024 | $35.7M | -82.3% | $-37.3M | -104.5% |
| Q3 2024 | $602.0K | — | $-85.9M | -14276.1% |
| Q2 2024 | $517.0K | -99.3% | $-126.4M | -24450.3% |
| Q1 2024 | $504.0K | -99.5% | $-116.6M | -23133.1% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $504000 | $517000 | $602000 | $35.7M | $865000 | $892000 | $889000 | $864000 |
| 同比增长 | -99.5% | -99.3% | N/A | -82.3% | 71.6% | 72.5% | 47.7% | -97.6% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $2.44B | $2.34B | $2.26B | $2.24B | $2.17B | $2.03B | $2.25B | $2.27B |
| 总负债 | $355.1M | $358.9M | $316.5M | $310.0M | $336.9M | $318.6M | $329.3M | $343.4M |
| 股东权益 | $2.08B | $1.98B | $1.94B | $1.93B | $1.83B | $1.71B | $1.92B | $1.92B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $109.8M | $-95.6M | $-106.9M | $-50.0M | $-53.9M | $-113.9M | $-84.6M | $-92.6M |